Tao T, Skiadopoulos M H, Durbin A P, Davoodi F, Collins P L, Murphy B R
Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0720, USA.
Vaccine. 1999 Mar 5;17(9-10):1100-8. doi: 10.1016/s0264-410x(98)00327-2.
The recovery of wild type and attenuated human parainfluenza type 3 (PIV3) recombinant viruses has made possible a new strategy to rapidly generate a live-attenuated vaccine virus fof PIV1. We previously replaced the coding sequences for the hemagglutinin-neuraminidase (HN) and fusion (F) proteins of PIV3 with those of PIV1 in the PIV3 antigenomic cDNA. This was used to recover a fully-viable, recombinant chimeric PIV3-PIV1 virus, termed rPIV3-1, which bears the major protective antigens of PIV1 and is wild type-like with regard to growth in cell culture and in hamsters [Tao T, Durbin AP, Whitehead SS, Davoodi F, Collins PL, Murphy BR. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoprotein have been replaced by those of PIV type 1. J Virol 1998;72:2955-2961]. Here we report the recovery of a derivative of rPIV3-1 carrying the three temperature-sensitive and attenuating amino acid coding changes found in the L gene of the live-attenuated cp45 PIV3 candidate vaccine virus. This virus, termed rPIV3-1.cp45L, is temperature-sensitive with a shut-off temperature of 38 degrees C, which is similar to that of the recombinant rPIV3cp45L, which possesses the same three mutations. rPIV3-1.cp45L is attenuated in the respiratory tract of hamsters to the same extent as rPIV3cp45L. Infection of hamsters with rPIV3-1.cp45L generated a moderate level of hemagglutination-inhibiting antibodies against wild type PIV1 and induced complete resistance to challenge with wild type PIV1. This demonstrates that this novel attenuated chimeric virus is capable of inducing a highly effective immune response against PIV1. It confirms previous observations that the surface glycoproteins of parainfluenza viruses are sufficient to induce a high level of resistance to homologous virus challenge. Unexpectedly, infection with recombinant chimeric virus rPIV3-1.cp45L or rPIV3-1, each bearing the surface glycoprotein genes of PIV1 and the internal genes of PIV3, also induced a moderate level of resistance to replication of wild type PIV3 challenge virus. This indicates that the internal genes of PIV3 can independently induce protective immunity against PIV3 in rodents, albeit a lower level of resistance than that induced by the surface glycoproteins. Thus, a reverse genetics system for PIV3 has been used successfully to produce a live attenuated PIV1 vaccine candidate that is attenuated and protective in experimental infection in hamsters.
野生型和减毒的人副流感病毒3型(PIV3)重组病毒的获得,使得一种快速产生PIV1减毒活疫苗病毒的新策略成为可能。我们之前在PIV3反基因组cDNA中,用PIV1的血凝素神经氨酸酶(HN)和融合(F)蛋白的编码序列替换了PIV3的相应编码序列。以此获得了一种完全可行的重组嵌合PIV3 - PIV1病毒,称为rPIV3 - 1,它携带PIV1的主要保护性抗原,在细胞培养物和仓鼠体内生长时类似野生型[Tao T, Durbin AP, Whitehead SS, Davoodi F, Collins PL, Murphy BR. 获得一种完全可行的嵌合人副流感病毒3型,其中血凝素神经氨酸酶和融合糖蛋白已被1型副流感病毒的相应蛋白所取代。《病毒学杂志》1998年;72:2955 - 2961]。在此,我们报告了rPIV3 - 1的一种衍生物的获得,该衍生物携带了减毒活cp45 PIV3候选疫苗病毒L基因中发现的三个温度敏感且具有减毒作用的氨基酸编码变化。这种病毒称为rPIV3 - 1.cp45L,具有温度敏感性,关闭温度为38℃,这与具有相同三个突变的重组rPIV3cp45L相似。rPIV3 - 1.cp45L在仓鼠呼吸道中的减毒程度与rPIV3cp45L相同。用rPIV3 - 1.cp45L感染仓鼠产生了中等水平的针对野生型PIV1的血凝抑制抗体,并诱导对野生型PIV1攻击产生完全抗性。这表明这种新型减毒嵌合病毒能够诱导针对PIV1的高效免疫反应。它证实了先前的观察结果,即副流感病毒的表面糖蛋白足以诱导对同源病毒攻击的高水平抗性。出乎意料的是,用携带PIV1表面糖蛋白基因和PIV3内部基因的重组嵌合病毒rPIV3 - 1.cp45L或rPIV3 - 1感染,也诱导了对野生型PIV3攻击病毒复制的中等水平抗性。这表明PIV3的内部基因能够在啮齿动物中独立诱导针对PIV3的保护性免疫,尽管抗性水平低于表面糖蛋白所诱导的水平。因此,PIV3的反向遗传系统已成功用于生产一种减毒活PIV1候选疫苗,该疫苗在仓鼠实验感染中具有减毒和保护作用。